Clinical Trial Update: Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the Bladder [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating modern immunotherapy for non-muscle invasive bladder cancer (urothelial carcinoma of the bladder) in BCG-unresponsive, BCG-r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bladder Cancer
• Urothelial Carcinoma of the Bladder

Snippet

Sponsor: Noah Hahn, M.D. | Conditions: Urothelial Carcinoma, Bladder Cancer | Phase 1, Phase 2 | Status: RECRUITING